Seer, Inc. (NASDAQ:SEER – Get Free Report) saw unusually large options trading on Monday. Stock investors purchased 4,887 call options on the company. This represents an increase of 9,674% compared to the average daily volume of 50 call options.
Seer Stock Up 39.2%
SEER traded up $0.64 on Monday, reaching $2.25. 22,081,452 shares of the company traded hands, compared to its average volume of 532,503. The company has a market cap of $123.98 million, a P/E ratio of -1.82 and a beta of 1.59. Seer has a one year low of $1.55 and a one year high of $2.41. The firm has a fifty day simple moving average of $1.78 and a two-hundred day simple moving average of $1.83.
Seer (NASDAQ:SEER – Get Free Report) last issued its earnings results on Wednesday, May 13th. The company reported ($0.30) EPS for the quarter, hitting analysts’ consensus estimates of ($0.30). The business had revenue of $2.79 million for the quarter, compared to the consensus estimate of $3.60 million. Seer had a negative net margin of 464.78% and a negative return on equity of 26.58%.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on the stock. TD Cowen upgraded shares of Seer to a “strong-buy” rating in a research report on Monday, April 13th. Canaccord Genuity Group started coverage on shares of Seer in a report on Monday, May 4th. They issued a “buy” rating and a $4.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Seer in a research note on Tuesday, April 21st. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Seer currently has a consensus rating of “Buy” and an average price target of $4.00.
View Our Latest Report on Seer
About Seer
Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.
The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.
See Also
- Five stocks we like better than Seer
- This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street
- AI Is Selling Off, But These 5 Stocks Could Benefit Next
- These 3 Stocks Offer Investors Exposure to the Functional Beverage Boom
- Alcoa’s $4.1 Billion South32 Deal: Opportunity Behind the 9% Drop
Receive News & Ratings for Seer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seer and related companies with MarketBeat.com's FREE daily email newsletter.
